Category: receptor_pharmacology
Explains the hot, red, prickling upper-body flush that lands ~15-30 min after immediate-release nicotinic acid — the most user-noticed effect of niacin and the reason most users abandon the lipid-lowering dose. Niacin binds GPR109A (HCA2 / HM74A / PUMA-G), a Gi/o-coupled GPCR identified as the niacin receptor by Tunaru 2003. In adipocytes GPR109A drives the anti-lipolytic effect (the lipid-lowering mechanism); but in skin it sits on epidermal Langerhans cells and keratinocytes, where activation triggers a phospholipase A2 → arachidonic acid → cyclooxygenase (COX-1 in Langerhans, COX-2 in keratinocytes) → prostaglandin D2 cascade (Benyo 2005, Benyo 2006, Hanson 2010). PGD2 released into the dermis activates DP1 receptors on cutaneous vascular smooth muscle → vasodilation, warmth, redness, and the characteristic tingle-itch. The flush is dose-dependent, saturable, and tachyphylactic (most users desensitize within 2-4 weeks). Aspirin 325 mg pre-dose blunts it by inhibiting COX, and laropiprant (a DP1 antagonist) was developed specifically to suppress it (Cheng 2006) — though laropiprant-niacin (Tredaptive / Cordaptive) was withdrawn after the HPS2-THRIVE outcome trial. Acipimox produces less flush than niacin per equivalent receptor occupancy; extended-release formulations (Niaspan) blunt peak plasma to stay below the flush threshold. Mechanism is distinct from histamine flush (antihistamines don't blunt it) and from carcinoid flush (no serotonin involvement).